Arbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $3.56, but opened at $3.45. Arbutus Biopharma shares last traded at $3.48, with a volume of 15,697 shares trading hands.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Arbutus Biopharma in a research report on Monday, November 18th. JMP Securities raised their price objective on shares of Arbutus Biopharma to $5.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. Jefferies Financial Group lifted their target price on Arbutus Biopharma from $5.00 to $7.00 and gave the company a "buy" rating in a report on Thursday, September 5th. Finally, Chardan Capital reiterated a "buy" rating and issued a $5.00 price objective (up previously from $4.50) on shares of Arbutus Biopharma in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $5.50.
View Our Latest Analysis on ABUS
Arbutus Biopharma Trading Up 2.0 %
The stock has a market cap of $672.69 million, a P/E ratio of -8.09 and a beta of 1.84. The business's 50 day moving average price is $3.75 and its two-hundred day moving average price is $3.70.
Institutional Trading of Arbutus Biopharma
Hedge funds and other institutional investors have recently modified their holdings of the business. Rubric Capital Management LP bought a new position in shares of Arbutus Biopharma during the second quarter valued at $5,195,000. State Street Corp lifted its stake in shares of Arbutus Biopharma by 50.2% in the third quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company's stock worth $16,967,000 after buying an additional 1,472,652 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Arbutus Biopharma by 218.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,212,246 shares of the biopharmaceutical company's stock valued at $4,667,000 after buying an additional 831,663 shares during the last quarter. Barclays PLC increased its position in shares of Arbutus Biopharma by 466.3% during the third quarter. Barclays PLC now owns 272,029 shares of the biopharmaceutical company's stock valued at $1,047,000 after acquiring an additional 223,995 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Arbutus Biopharma during the third quarter valued at $754,000. 43.79% of the stock is owned by hedge funds and other institutional investors.
Arbutus Biopharma Company Profile
(
Get Free Report)
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
See Also
Before you consider Arbutus Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arbutus Biopharma wasn't on the list.
While Arbutus Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
